Revenue +6% vs. ABGSCe, EBITDA -23% vs. ABGSCe ACV growth of 3% q-o-q Targets 15-20% org.
Redeye comments on I-Tech’s Q2 figures, with a beat to our expectations.
Redeye states the report was largely inline with our expectations and the preannounced results.
Raute’s Q2 figures were a bit of a mixed bag relative to our estimates as top line and profitability...
Sales in Q2’23 of SEK 7.4m were softer than we expected.
Q2 EBIT of SEK 41m (+67% y-o-y) vs ABGSCe at SEK 70m Expect full-year starts of ~670 units, +18% vs ...
Redeye updates its view on Beyond Frames after the Q2’2023 report.
Redeye argues that the Q2 report from Zwipe was weaker than we expected both in terms of sales and c...
Strax's recent divestment of 50.1% of its Distribution segment marks a significant move towards stre...
Redeye is now a bit more cautious on the near-term outlook as the sawmill industry is facing a chall...
Redeye notes that Sdiptech has concluded the issuance of a SEK600m sustainability linked bond.
Redeye updates its estimates following Surgical Science’s Q2 2023 report, which featured a ‘mixed ba...
52% adj. EBITA growth driven by non-SE divisions '23e-'25e adj.
Under sommaren kommunicerade Learning to Sleep att bolaget avser att förvärva samtliga aktier i Bonz...
Strong AUM growth despite tough market EBIT cut for 2023-24e on persistent weak activity 2023e EV/EB...
In Q2-23, STENOCARE delivered a sales growth of 279% Y-Y, amounting to DKK 1.
Q2 dominerades av leveranser från pågående projekt.
CirChem har publicerat bolagets delårsrapport för det andra kvartalet 2023 och visar på fortsatta fr...
A rare miss on sales growth in Q2 Monopoly GO! and increased distribution excite H2 outlook for sale...
Fastighetsbolaget Eastnine aviserade en avyttring av det ryska innehavet MFG.
